In vitro and in vivo characterization of human serum albumin-based PEGylated nanoparticles for BDNF and NT3 codelivery

The utilization of neurotrophins in medicine shows significant potential for addressing neurodegenerative conditions, such as age-related macular degeneration (AMD). However, the therapeutic use of neurotrophins has been restricted due to their short half-life. Here, we aimed to synthesize PEGylated...

Full description

Saved in:
Bibliographic Details
Published in:International journal of biological macromolecules 2024-04, Vol.265 (Pt 2), p.130726-130726, Article 130726
Main Authors: Dąbkowska, Maria, Stukan, Iga, Kosiorowska, Alicja, Szatanik, Alicja, Łuczkowska, Karolina, Machalińska, Anna, Machaliński, Bogusław
Format: Article
Language:English
Subjects:
Albumin
AMD
BDNF delivery
NT3 delivery
PEGylated HSA nanoparticle
Protein delivery system
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The utilization of neurotrophins in medicine shows significant potential for addressing neurodegenerative conditions, such as age-related macular degeneration (AMD). However, the therapeutic use of neurotrophins has been restricted due to their short half-life. Here, we aimed to synthesize PEGylated nanoparticles based on electrostatic-driven interactions between human serum albumin (HSA), a carrier for adsorption; neurotrophin-3 (NT3); and brain-derived neurotrophic factor (BDNF). Electrophoretic (ELS) and multi-angle dynamic light scattering (MADLS) revealed that the PEGylated HSA-NT3-BDNF nanoparticles ranged from 10 to 430 nm in diameter and exhibited a low polydispersity index (
ISSN:0141-8130
1879-0003
DOI:10.1016/j.ijbiomac.2024.130726